Decreases in cervical intraepithelial neoplasia (CIN) on the population level among patients vaccinated for the human papillomavirus (HPV) should be considered.
Only 1 in 5 parents support laws requiring human papillomavirus (HPV) vaccination for school attendance.
Researchers found that vaccination for HPV should be given in 2 doses, at least 6 months apart for routine vaccinations of young girls.
The human papillomavirus (HPV)-16/18 vaccine appears to protect against the viral strain even after one or two doses.
Many American college students don't fully understand the threat posed by the human papillomavirus (HPV) or their risk for infection.
Males benefit indirectly when girls are immunized against human papillomavirus (HPV).
The quadrivalent human papillomavirus (HPV4) vaccine appears to be cost-effective for the prevention of oropharyngeal cancer (OPC).
Mixed views in relation to explaining causal role of human papillomavirus (HPV) in oropharyngeal cancer.
The National Cancer Institute (NCI) has funded $3.5 million for the development of a new human papillomavirus (HPV) vaccine.
[Clin Med Insights Oncol] HPV is a risk factor for anal intraepithelial neoplasia (AIN). Etiology, anatomy, pathogenesis, management of squamous cell carcinoma (SCC) discussed.
Results of ADXS-HPV with standard chemo and radiotherapy for HPV-associated anal cancer who have a high risk of recurrence.
Research suggests the human papillomavirus (HPV) vaccine could prevent 90 percent of cervical malignancies.
Less invasive method may increase screening rates for cervical cancer, researchers say.
A review of data suggests that HPV testing alone every 3 years provides a high level of reassurance against cervical cancer.
Registry data show increase in incidence rates of HPV-related oropharyngeal and anal cancers.
Risk for venous thromboembolism appears to be no higher after quadrivalent HPV vaccination.
For patients with oropharynx cancer, HPV positivity is associated with improved survival after disease progression.
HPV test can detect 95% of precancerous lesions, and cotesting with Pap detects more disease.
Two-thirds of surveyed adults reported being not very or not at all knowledgeable about head and neck cancer.
CHICAGO, IL—Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients' quality of life.
Almost 70% of healthy humans infected with more than 100 strains of human papillomavirus.
Oral HPV, HPV16 DNA commonly detected in patients with oropharyngeal cancer, but not their partners.
The FDA has approved Roche's cobas HPV Test, the first human papillomavirus (HPV) DNA test for women ages >25 that can be used alone to help assess the need for additional diagnostic testing for cervical cancer.
Most oropharyngeal cancers in the United States diagnosed between 1995 and 2005 were positive for human papillomavirus, specifically HPV 16 or 18.
Patients with HPV-positive OPSCC report different symptoms than those with HPV-negative OPSCC, which may have an effect on how early the disease is diagnosed.
Experts voted 13-0 that Roche's test was safe and effective as first step in cervical cancer screening.
HPV vaccination is associated with reduced risk of atypic, atypia+ or cervical intraepithelial neoplasia grade 2 or 3.
The HPV vaccine protects against cancers of the cervix, throat, rectum, and penis, but too few girls and boys are getting vaccinated.
Three-year risks of CIN 2+ and CIN+ were 0.4% and 0.0%, respectively, after infection
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Resveratrol and Cancer
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- Global Burden of Myeloma Increasing, Access to Treatments Lacking
- ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks
- Adding Rituximab to Prednisolone May Improve Long-Term Response in Immune Thrombocytopenia
- FDA Updates Restrictions for Pembrolizumab, Atezolizumab in Urothelial Carcinoma
- Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
- Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer